Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.
antitumor
gastric cancer
luteolin (Lut)
patient-derived organoids (PDOs)
Journal
Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
03
07
2023
received:
06
03
2023
accepted:
04
07
2023
medline:
10
11
2023
pubmed:
20
7
2023
entrez:
20
7
2023
Statut:
ppublish
Résumé
Luteolin (Lut) has been shown to inhibit gastric cancer (GC); however, its efficacy compared to other clinical drugs has not been examined in human samples. This study aimed to elucidate the antitumor activity of Lut in GC patient-derived organoids (PDOs). PDOs were established from GC cancer tissues, and the characterization of tissues and PDOs was performed using whole-exome sequencing. Drug sensitivity tests were performed by treating PDOs with Lut, norcantharidin (NCTD), and carboplatin (CP). RNA sequencing of PDOs was performed to elucidate the antitumor mechanism of Lut, which was further verified in three GC cell lines. Eleven PDOs were successfully constructed, and were highly consistent with the pathophysiology and genetic changes in the corresponding tumors. The IC50s of Lut, NCTD, and CP of PDOs were 27.19, 23.9, and 37.87 μM, respectively. Lut treatment upregulated FOXO3, DUSP1, and CDKN1A expression and downregulated IL1R1 and FGFR4 expression in GC cell lines, which was consistent with the results of PDOs. We demonstrate that Lut exerted stronger antitumor effects than CP, but a similar effect to that of NCTD, which was obtained in an in vitro PDO system. Additionally, Lut exerted varying degrees of antitumor effects against the PDOs, thereby indicating that PDO may be a useful preclinical drug screening tool for personalized treatment.
Substances chimiques
Luteolin
KUX1ZNC9J2
Carboplatin
BG3F62OND5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5315-5327Subventions
Organisme : National Natural Science Foundation of China
ID : 82070577
Informations de copyright
© 2023 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.
Références
Chen, P., Zhang, X., Ding, R., Yang, L., Lyu, X., Zeng, J., Lei, J. H., Wang, L., Bi, J., Shao, N., Shu, D., Wu, B., Wu, J., Yang, Z., Wang, H., Wang, B., Xiong, K., Lu, Y., Fu, S., … Deng, C. (2021). Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer. Advanced Science, 8(22), e2101176. https://doi.org/10.1002/advs.202101176
Chi, J., Jiang, Z., Qiao, J., Zhang, W., Peng, Y., Liu, W., & Han, B. (2019). Antitumor evaluation of carboxymethyl chitosan based norcantharidin conjugates against gastric cancer as novel polymer therapeutics. International Journal of Biological Macromolecules, 136, 1-12. https://doi.org/10.1016/j.ijbiomac.2019.05.216
Demyan, L., Habowski, A. N., Plenker, D., King, D. A., Standring, O. J., Tsang, C., St. Surin, L., Rishi, A., Crawford, J. M., Boyd, J., Pasha, S. A., Patel, H., Galluzzo, Z., Metz, C., Gregersen, P. K., Fox, S., Valente, C., Abadali, S., Matadial-Ragoo, S., … Weiss, M. J. (2022). Pancreatic cancer patient-derived organoids can predict response to neoadjuvant chemotherapy. Annals of Surgery, 276(3), 450-462. https://doi.org/10.1097/SLA.0000000000005558
Feng, H., Gu, Z., Li, Q., Liu, Q., Yang, X., & Zhang, J. (2019). Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis. Journal of Ovarian Research, 12(1), 35. https://doi.org/10.1186/s13048-019-0508-2
Fujii, E., Yamazaki, M., Kawai, S., Ohtani, Y., Watanabe, T., Kato, A., & Suzuki, M. (2018). A simple method for histopathological evaluation of organoids. Journal of Toxicologic Pathology, 31(1), 81-85. https://doi.org/10.1293/tox.2017-0060
Gendrisch, F., Esser, P. R., Schempp, C. M., & Wölfle, U. (2021). Luteolin as a modulator of skin aging and inflammation. BioFactors, 47(2), 170-180. https://doi.org/10.1002/biof.1699
Grossman, J. E., Muthuswamy, L., Huang, L., Akshinthala, D., Perea, S., Gonzalez, R. S., Tsai, L. L., Cohen, J., Bockorny, B., Bullock, A. J., Schlechter, B., & Hidalgo, M. (2022). Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer. Clinical Cancer Research, 28(4), 708-718. https://doi.org/10.1158/1078-0432.CCR-20-4116
Hu, Y., Sui, X., Song, F., Li, Y., Li, K., Chen, Z., Yang, F., Chen, X., Zhang, Y., Wang, X., Liu, Q., Li, C., Zou, B., Chen, X., Wang, J., & Liu, P. (2021). Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nature Communications, 12(1), 2581. https://doi.org/10.1038/s41467-021-22676-1
Imran, M., Rauf, A., Abu-Izneid, T., Nadeem, M., Shariati, M. A., Khan, I. A., Imran, A., Orhan, I. E., Rizwan, M., Atif, M., Gondal, T. A., & Mubarak, M. S. (2019). Luteolin, a flavonoid, as an anticancer agent: A review. Biomedicine & Pharmacotherapy, 112, 108612. https://doi.org/10.1016/j.biopha.2019.108612
Ji, L., Shen, W., Zhang, F., Qian, J., Jiang, J., Weng, L., Tan, J., Li, L., Chen, Y., Cheng, H., & Sun, D. (2021). Worenine reverses the Warburg effect and inhibits colon cancer cell growth by negatively regulating HIF-1α. Cellular & Molecular Biology Letters, 26(1), 19. https://doi.org/10.1186/s11658-021-00263-y
Jiang, D. M., Sim, H. W., Espin-Garcia, O., Chan, B. A., Natori, A., Lim, C. H., Moignard, S., Chen, E. X., Liu, G., Darling, G., Swallow, C. J., & Elimova, E. (2021). Chemoradiotherapy using carboplatin plus paclitaxel versus cisplatin plus fluorouracil for esophageal or gastroesophageal junction cancer. Oncology, 99(1), 49-56. https://doi.org/10.1159/000510446
Jie, M., Wu, Y., Gao, M., Li, X., Liu, C., Ouyang, Q., Tang, Q., Shan, C., Lv, Y., Zhang, K., Dai, Q., Chen, Y., Zeng, S., Li, C., Wang, L., He, F., Hu, C., & Yang, S. (2020). CircMRPS35 suppresses gastric cancer progression via recruiting KAT7 to govern histone modification. Molecular Cancer, 19(1), 56. https://doi.org/10.1186/s12943-020-01160-2
Kanton, S., Boyle, M. J., He, Z., Santel, M., Weigert, A., Sanchís-Calleja, F., Guijarro, P., Sidow, L., Fleck, J. S., Han, D., Qian, Z., Heide, M., Huttner, W. B., Khaitovich, P., Pääbo, S., Treutlein, B., & Camp, J. G. (2019). Organoid single-cell genomic atlas uncovers human-specific features of brain development. Nature, 574(7778), 418-422. https://doi.org/10.1038/s41586-019-1654-9
Kim, J., Koo, B. K., & Knoblich, J. A. (2020). Human organoids: Model systems for human biology and medicine. Nature Reviews. Molecular Cell Biology, 21(10), 571-584. https://doi.org/10.1038/s41580-020-0259-3
Li, X., He, X., Chen, S., Le, Y., Bryant, M. S., Guo, L., Witt, K. L., & Mei, N. (2021). The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells. Toxicology Letters, 344, 58-68. https://doi.org/10.1016/j.toxlet.2021.03.006
Li, X., Sun, Z., Peng, G., Xiao, Y., Guo, J., Wu, B., Li, X., Zhou, W., Li, J., Li, Z., Bai, C., Zhao, L., Han, Q., Zhao, R. C., & Wang, X. (2022). Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer. Theranostics, 12(2), 620-638. https://doi.org/10.7150/thno.60540
Liu, Q., Sun, H., Li, X., Sheng, H., & Zhu, L. (2022). Strategies for solubility and bioavailability enhancement and toxicity reduction of Norcantharidin. Molecules, 27(22), 7740. https://doi.org/10.3390/molecules27227740
Lu, J., Li, G., He, K., Jiang, W., Xu, C., Li, Z., Wang, H., Wang, W., Wang, H., Teng, X., & Teng, L. (2015). Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer. Journal of Translational Medicine, 13, 42. https://doi.org/10.1186/s12967-015-0398-z
Lu, X., Li, Y., Li, X., & Aisa, H. A. (2017). Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways in gastric cancer. Oncology Letters, 14(2), 1993-2000. https://doi.org/10.3892/ol.2017.6380
Ma, J., Chen, X., Zhu, X., Pan, Z., Hao, W., Li, D., Zheng, Q., & Tang, X. (2022). Luteolin potentiates low-dose oxaliplatin-induced inhibitory effects on cell proliferation in gastric cancer by inducing G2/M cell cycle arrest and apoptosis. Oncology Letters, 23(1), 16. https://doi.org/10.3892/ol.2021.13134
Ouyang, S., Li, H., Lou, L., Huang, Q., Zhang, Z., Mo, J., Li, M., Lu, J., Zhu, K., Chu, Y., Ding, W., & Zhang, X. (2022). Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biology, 52, 102317. https://doi.org/10.1016/j.redox.2022.102317
Preusser, P., Wilke, H., Achterrath, W., Lenaz, L., Stahl, M., Casper, J., Meyer, H. J., Meyer, J., Blum, M., & Schmoll, H. J. (1990). Phase II study of carboplatin in untreated inoperable advanced stomach cancer. European Journal of Cancer, 26(10), 1108-1109. https://doi.org/10.1016/0277-5379(90)90067-4
Rossi, A., Di Maio, M., Chiodini, P., Rudd, R. M., Okamoto, H., Skarlos, D. V., Fruh, M., Qian, W., Tamura, T., Samantas, E., Shibata, T., Perrone, F., Gallo, C., Gridelli, C., Martelli, O., & Lee, S. M. (2012). Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. Journal of Clinical Oncology, 30(14), 1692-1698. https://doi.org/10.1200/JCO.2011.40.4905
Sexton, R. E., Al Hallak, M. N., Diab, M., & Azmi, A. S. (2020). Gastric cancer: A comprehensive review of current and future treatment strategies. Cancer Metastasis Reviews, 39(4), 1179-1203. https://doi.org/10.1007/s10555-020-09925-3
Shi, X., Li, Y., Yuan, Q., Tang, S., Guo, S., Zhang, Y., He, J., Zhang, X., Han, M., Liu, Z., Zhu, Y., Gao, S., Wang, H., Xu, X., Zheng, K., Jing, W., Chen, L., Wang, Y., Jin, G., & Gao, D. (2022). Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Nature Communications, 13(1), 2169. https://doi.org/10.1038/s41467-022-29857-6
Shimoi, K., Okada, H., Furugori, M., Goda, T., Takase, S., Suzuki, M., Hara, Y., Yamamoto, H., & Kinae, N. (1998). Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Letters, 438(3), 220-224. https://doi.org/10.1016/s0014-5793(98)01304-0
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020). Gastric cancer. Lancet, 396(10251), 635-648. https://doi.org/10.1016/S0140-6736(20)31288-5
Song, S., Su, Z., Xu, H., Niu, M., Chen, X., Min, H., Zhang, B., Sun, G., Xie, S., Wang, H., & Gao, Q. (2017). Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. Cell Death & Disease, 8(2), e2612. https://doi.org/10.1038/cddis.2017.38
Suarez-Martinez, E., Suazo-Sanchez, I., Celis-Romero, M., & Carnero, A. (2022). 3D and organoid culture in research: Physiology, hereditary genetic diseases and cancer. Cell & Bioscience, 12(1), 39. https://doi.org/10.1186/s13578-022-00775-w
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E., Burkhart, R. A., Denroche, R. E., Jang, G. H., Miyabayashi, K., & Tuveson, D. A. (2018). Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discovery, 8(9), 1112-1129. https://doi.org/10.1158/2159-8290.CD-18-0349
Tuveson, D., & Clevers, H. (2019). Cancer modeling meets human organoid technology. Science, 364(6444), 952-955. https://doi.org/10.1126/science.aaw6985
Veninga, V., & Voest, E. E. (2021). Tumor organoids: Opportunities and challenges to guide precision medicine. Cancer Cell, 39(9), 1190-1201. https://doi.org/10.1016/j.ccell.2021.07.020
Wei, L., Sun, J., Zhang, N., Zheng, Y., Wang, X., Lv, L., Liu, J., Xu, Y., Shen, Y., & Yang, M. (2020). Noncoding RNAs in gastric cancer: Implications for drug resistance. Molecular Cancer, 19(1), 62. https://doi.org/10.1186/s12943-020-01185-7
Wu, B., Zhang, Q., Shen, W., & Zhu, J. (2008). Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. Molecular and Cellular Biochemistry, 313(1-2), 125-132. https://doi.org/10.1007/s11010-008-9749-x
Xu, H., Lyu, X., Yi, M., Zhao, W., Song, Y., & Wu, K. (2018). Organoid technology and applications in cancer research. Journal of Hematology & Oncology, 11(1), 116. https://doi.org/10.1186/s13045-018-0662-9
Yajie, D., Feng, L., Zhaoyan, L., Yan, X., Nida, C., Guangao, Z., Rui, W., & Aiguang, Z. (2023). Efficacy of luteolin on the human gastric cancer cell line MKN45 and underlying mechanism. Journal of Traditional Chinese Medicine, 43(1), 34-41. https://doi.org/10.19852/j.cnki.jtcm.2023.01.005
Yan, H. H. N., Siu, H. C., Law, S., Ho, S. L., Yue, S. S. K., Tsui, W. Y., Chan, D., Chan, A. S., Ma, S., Lam, K. O., Bartfeld, S., & Leung, S. Y. (2018). A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell, 23(6), 882-897.e11. https://doi.org/10.1016/j.stem.2018.09.016
Yao, W., Qiu, H., Cheong, K., & Zhong, S. (2022). Advances in anti-cancer effects and underlying mechanisms of marine algae polysaccharides. International Journal of Biological Macromolecules, 221, 472-485. https://doi.org/10.1016/j.ijbiomac.2022.09.055
Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., Pan, M., & Hua, G. (2020). Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell, 26(1), 17-26.e6. https://doi.org/10.1016/j.stem.2019.10.010
Zang, M., Hu, L., Fan, Z., Wang, H., Zhu, Z., Cao, S., Wu, X. Y., Li, J. F., Su, L. P., Li, C., Zhu, Z. G., & Liu, B. (2017). Luteolin suppresses gastric cancer progression by reversing epithelial-mesenchymal transition via suppression of the Notch signaling pathway. Journal of Translational Medicine, 15(1), 52. https://doi.org/10.1186/s12967-017-1151-6
Zang, M., Hu, L., Zhang, B., Zhu, Z., Li, J., Zhu, Z., Yan, M., & Liu, B. (2017). Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1-VEGF signaling in gastric cancer. Biochemical and Biophysical Research Communications, 490(3), 913-919. https://doi.org/10.1016/j.bbrc.2017.06.140
Zhang, J., Zhou, Y., & Ma, Z. (2021). Multi-target mechanism of Tripteryguim wilfordii hook for treatment of ankylosing spondylitis based on network pharmacology and molecular docking. Annals of Medicine, 53(1), 1090-1098. https://doi.org/10.1080/07853890.2021.1918345
Zhang, P., Gu, Y., Fang, H., Cao, Y., Wang, J., Liu, H., Zhang, H., Li, H., He, H., Li, R., Lin, C., & Xu, J. (2022). Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer. Journal for Immunotherapy of Cancer, 10(2), e004047. https://doi.org/10.1136/jitc-2021-004047
Zhang, X., Soutto, M., Chen, Z., Bhat, N., Zhu, S., Eissmann, M. F., Ernst, M., Lu, H., Peng, D., Xu, Z., & El-Rifai, W. (2022). Induction of fibroblast growth factor receptor 4 by helicobacter pylori via signal transducer and activator of transcription 3 with a feedforward activation loop involving SRC signaling in gastric cancer. Gastroenterology, 163(3), 620-636.e9. https://doi.org/10.1053/j.gastro.2022.05.016
Zheng, L., Yang, M., Kuo, C., Lin, C., Fan, M., Chou, Y., Lu, H. F., Huang, W. W., Peng, S. F., & Chung, J. (2016). Norcantharidin-induced apoptosis of AGS human gastric cancer cells through reactive oxygen species production, and caspase- and mitochondria-dependent signaling pathways. Anticancer Research, 36(11), 6031-6042. https://doi.org/10.21873/anticanres.11192
Zhou, P., Li, L., Luo, S., Jiang, H., & Zeng, S. (2008). Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. Journal of Agricultural and Food Chemistry, 56(1), 296-300. https://doi.org/10.1021/jf072612+
Zivanovic, O., Chi, D. S., Zhou, Q., Iasonos, A., Konner, J. A., Makker, V., Grisham, R. N., Brown, A. K., Nerenstone, S., Diaz, J. P., Schroeder, E. D., Langstraat, C. L., Paroder, V., Lakhman, Y., Soldan, K., Su, K., Gardner, G. J., Andikyan, V., Guo, J., … O'Cearbhaill, R. E. (2021). Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: An MSK team ovary phase II study. Journal of Clinical Oncology, 39(23), 2594-2604. https://doi.org/10.1200/JCO.21.00605
Zou, J., Wang, S., Chai, N., Yue, H., Ye, P., Guo, P., Li, F., Wei, B., Ma, G., Wei, W., & Linghu, E. (2022). Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations. Journal of Nanobiotechnology, 20(1), 233. https://doi.org/10.1186/s12951-022-01431-8